Romdhane K, Zola M, Matet A, et al. - Using multimodal imaging, researchers assessed the impact of anti-vascular endothelial growth factor (VEGF) therapy on choroidal neovascularisation (CNV) complicating central serous chorioretinopathy (CSC) and identified possible predictive factors of the treatment response. For this retrospective study, they reviewed data of 27 eyes with CNV complicating CSC treated with anti-VEGF therapy (either ranibizumab or aflibercept). Like the subretinal fluid, central retinal thickness (CRT) was significantly reduced by 32 ± 15 days after 2.8 ± 1.3 injections. In 45% of cases, complete fluid resorption was noted. Greater CRT at baseline, greater amount of subretinal fluid, a shorter period of retinal fluid and female gender were identified as predictors for CRT reduction by univariate analysis. According to findings, the anti-VEGF response was highly variable and often incomplete, indicating that the fluid accumulation was not solely caused by CNV. Anti-VEGF indication in CNV associated with CSC may be driven by predictive factors.